Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05652036 · ClinicalTrials.gov registry record · Phase 4
Procedural Discomfort Related to Number of Intradetrusor Botox Injections
A Phase 4 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 108
- Enrollment target
NCT05652036 is a Phase 4 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 108 participants.
The verdict
NCT05652036, a Phase 4 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 108 participants
- Enrollment target
Study Summary
Injection of intradetrusor OnabotulinumtoxinA (BTX-A) is a highly efficacious therapy with a reliable safety profile and demonstrable improvements in subjective and objective measures for overactive bladder (OAB) symptom control. This procedure can be performed in the office with an evidence-based standard dosing of 100 units for idiopathic OAB. This is a single-blinded, randomized control trial is to evaluate and optimize the technique for performing intradetrusor injections of BTX-A for idiopathic OAB. This trial proposes two different reconstitution and injection schema to study patient-centered outcomes related to procedural discomfort and symptom relief.
Interventions
- BIOLOGICAL Intradetrusor Botox Injections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2023-05-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05652036
The ClinicalTrials.gov registry entry for NCT05652036 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intradetrusor Botox Injections is the first listed.
NCT05652036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05652036 about?
NCT05652036 is a clinical study titled "Procedural Discomfort Related to Number of Intradetrusor Botox Injections". Injection of intradetrusor OnabotulinumtoxinA (BTX-A) is a highly efficacious therapy with a reliable safety profile and demonstrable improvements in subjective and objective measures for overactive bladder (OAB) symptom control. This procedure can be performed in the office with an evidence-based s...
What is the current status of trial NCT05652036?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2022-07-07. Estimated completion is 2023-05-15.
What interventions are being tested in trial NCT05652036?
The interventions under investigation include: Intradetrusor Botox Injections (BIOLOGICAL).
Who is sponsoring clinical trial NCT05652036?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.